Technical Insights on Biotech Stocks -- Conatus Pharma, Immunomedics, INSYS Therapeutics, and InVivo Therapeutics

NEW YORK, October 17, 2017 /PRNewswire/ --

If you want a Stock Review on CNAT, IMMU, INSY, or NVIV then come over to and sign up for your free customized report. On Monday, benchmark US indices were in bullish colors as the NASDAQ Composite closed the trading session up 0.28%; the Dow Jones Industrial Average edged 0.37% higher; and the S&P 500 was up 0.18%. %. US markets saw five out of nine sectors finishing the day in green, two in red, and two in neutral territory. Pre-market today, reviews these four Biotechnology stocks: Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), Immunomedics Inc. (NASDAQ: IMMU), INSYS Therapeutics Inc. (NASDAQ: INSY), and InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV). Access's free research reports for this morning's stocks line-up at:

Conatus Pharmaceuticals 

San Diego, California headquartered Conatus Pharmaceuticals Inc.'s stock finished Monday's session 0.95% higher at $5.32. A total volume of 160,505 shares was traded. The Company's shares have advanced 180.00% in the last twelve months. The stock is trading below its 50-day moving average by 2.75%. Furthermore, shares of Conatus Pharma, which focuses on the development and commercialization of novel medicines to treat liver diseases in the US, have a Relative Strength Index (RSI) of 43.79. Free research report on CNAT is available at:


Shares in Morris Plains, New Jersey headquartered Immunomedics Inc. ended at $11.18, down 4.61% from the last trading session. The stock recorded a trading volume of 1.86 million shares. The Company's shares have gained 22.59% over the previous three months, 388.21% in the last twelve months, and 204.63% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 1.18% and 47.51%, respectively. Moreover, shares of Immunomedics, which focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders, and other diseases, have an RSI of 45.64. The complimentary research report on IMMU can be downloaded at:

INSYS Therapeutics 

Chandler, Arizona headquartered INSYS Therapeutics Inc.'s stock ended yesterday's session 1.72% lower at $7.42 with a total trading volume of 569,497 shares. The stock is trading below its 50-day moving average by 18.68%. Additionally, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 30.79.

On October 11th, 2017, research firm RBC Capital Markets reiterated its 'Outperform' rating on the Company's stock, with a target price of $14 per share. Visit us today and access our complete research report on INSY at:

InVivo Therapeutics Holdings 

On Monday, shares in Cambridge, Massachusetts headquartered InVivo Therapeutics Holdings Corp. recorded a trading volume of 73,786 shares. The stock finished the day flat at $1.50. The Company's shares have advanced 15.38% in the last one month. The stock is trading above its 50-day moving average by 9.93%. Furthermore, shares of InVivo Therapeutics, which focus on developing and commercializing biopolymer scaffolding devices for the treatment of spinal cord injuries, have an RSI of 53.88. Get free access to your research report on NVIV at:


Daily Stock Tracker: 

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

DST has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA(R) charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


        For any questions, inquiries, or comments reach out to us directly. If you're a company
         we are covering and wish to no longer feature on our coverage list contact us via
         email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: 
        Phone number: (207)331-3313 
        Office Address: 377 Rivonia Boulevard, Rivonia, South Africa 


CFA(R) and Chartered Financial Analyst(R) are registered trademarks owned by CFA Institute.